Switzerland’s Novartis buying San Diego biotech Avidity in $12 billion cash deal
Novartis staff celebrate the company’s 25 years in San Diego outside the Genomics Institute of the Novartis Research…
Glomerulonephritis Market Projected to Surge by 2034 with Rising Demand for Targeted Therapies
The glomerulonephritis market is witnessing steady growth driven by the increasing prevalence of chronic kidney diseases and improved…
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for…
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III…
Novartis receives approval for first malaria medicine for newborn babies and young infants
Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight…